Article Text
DTB commentary
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
Abstract
Commentary on: Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57.
Commentary by: Dr Emma Magavern and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK
Series Editor: Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK
- cardiovascular diseases
- diabetes mellitus